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This editorial refers to ‘Edoxaban vs. warfarin in patients
with atrial fibrillation on amiodarone: a subgroup analysis
of the ENGAGE AF-TIMI 48 trial’†, by J. Steffel et al., on
page 2239.
Stroke prevention using oral anticoagulation is a highly effective
intervention to improve outcomes among patients with atrial fibril-
lation (AF), the most common cardiac arrhythmia in the popula-
tion.1,2 Compared with placebo, the use of vitamin K antagonists
reduces the risk of stroke by 64% in patients with AF, but significantly
increases the risk of major and life-threatening bleeding.3 In recent
years, new oral anticoagulants with a more favourable risk–benefit
profile have been developed and tested in large randomized
trials, further improving anticoagulation treatment among patients
with AF.
One of these studies was the Effective Anticoagulation with
Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in
Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial, a large rando-
mized trial comparing the efficacy and safety of two dosing regimens
of edoxaban with warfarin among AF patients at increased risk of
stroke. Compared with warfarin, this trial established the non-
inferiority of both regimens with regard to prevention of stroke
and systemic embolism, with the advantage of significantly lower
rates of major bleeding associated with both dosing strategies.4
However, the low-dose edoxaban strategy was associated with a
highly significant 41% increased risk of ischemic stroke, making the
clinical use of this regimen less straightforward, despite its profound
reduction of bleeding complications and a significant reduction in
all-cause mortality.
Thus interventions to improve the efficacy of the low-dose edox-
aban strategy without compromising too much its safety could have
an important impact on clinical practice.
Drug–drug interactions that moderately increase edoxaban drug
concentrationsmay help to achieve this goal. In this issue of the jour-
nal, a subgroup analysis of the ENGAGE AF-TIMI 48 trial is pre-
sented that investigated the effect of amiodarone, a widely used
antiarrhythmic drug with multiple drug–drug interactions, on the
efficacy and safety of edoxaban for stroke prevention in AF pa-
tients.5 The authors of this study showed that among the 2492 par-
ticipants (11.8%) receiving amiodarone at baseline, low-dose
edoxaban was associated with a significant reduction in the risk of
stroke or systemic embolism [hazard ratio (HR) 0.60, 95% confi-
dence interval (CI) 0.36, 0.99], without increasing the risk of ische-
mic stroke (HR 0.96, 95% CI 0.54, 1.70). In contrast, the risk of
stroke or systemic embolism was significantly higher among patients
in the low-dose edoxaban arm not taking amiodarone (HR 1.20,
95% CI 1.03, 1.40; P-value for interaction 0.01). On the other
hand, the principal safety endpoint of major bleeding was similar
among patients taking or not taking amiodarone (HR 0.35, 95% CI
0.21, 0.59 and HR 0.53, 95% CI 0.46, 0.61; P-value for interaction
0.13). As expected, concomitant use of amiodarone increased
edoxaban concentrations in the low-dose arm (27.3+24.5 ng/mL
vs. 21.9+ 20.8 ng/mL, P, 0.001) and in the high-dose arm
(58.5+53.2 ng/ml vs. 43.2+ 41.1 ng/mL, P, 0.001).
Now the key question is whether concomitant use of amiodarone
and low-dose edoxaban achieves a “sweet spot” between protec-
tion from ischemic events and bleeding, as suggested by the authors,
or whether the observed findings can be explained by chance. In my
view, the second option is more likely for several reasons. First, as
appropriately stated by the authors, study participants were not ran-
domized to amiodarone treatment, and the amiodarone subgroup
was relatively small and only one of several subgroups that were as-
sessed, such that chance, bias or confounding may have contributed
to these differential findings. Second, the significant interaction in ef-
ficacy in the low-dose edoxaban group was not observed in the
high-dose group despite a larger difference in edoxaban concentra-
tions between amiodarone users and non-users. In addition,
co-administration of amiodarone had no effect on the incidence
of major bleeding events, the principal safety endpoint. The authors
hypothesize that the increase in plasma levels caused by
co-administration of amiodarone and low-dose edoxaban occurs
at an inflection point in the dose–response curve for efficacy but
falls within the flatter part of the dose–response curve for bleeding,
while the increase in concentration in high-dose edoxaban patients
taking amiodarone occurs during the flat portion of the dose–
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response curve for efficacy. While appealing, this hypothesis seems
not to be consistent with the findings of a recently published paper
from the ENGAGEAF-TIMI 48 trial, where therewas a linear dose–
response curve for both efficacy and safety across a wide range of
edoxaban concentrations, without evidence of an inflection point
or saturation effect.6 In this analysis, the dose–response curve for
bleeding was actually steeper than that for stroke or systemic em-
bolism, suggesting that a relevant effect of amiodarone should
have been observed primarily for the bleeding endpoint. Third,
while differences in edoxaban concentrations were statistically sig-
nificant, they were rather small on an absolute scale. Being on high-
dose vs. low-dose edoxaban had a far greater impact on edoxaban
concentrations than being on amiodarone vs. no amiodarone as
indicated above. Nevertheless, differences in the absolute rates of
the primary endpoint among those taking and not taking amiodar-
one in the low-dose arm (1.12% per year vs. 2.16% per year) are
on the same order of magnitude as those between the 60-mg
dose and the 15-mg dose (1.0% per year vs. 2.36% per year), where
differences in mean edoxaban concentrations were far greater (48.5
vs. 16.0 ng/mL).6
Nonetheless, the current article is still of clinical importance for
several reasons. First, it shows that co-prescription of amiodarone
does not have any visible adverse effects on the efficacy and safety
of edoxaban. This is a very reassuring finding for those AF patients
who need both amiodarone and effective stroke prevention.
Although post-marketing studies are usually not randomized and
therefore subject to bias, they will be an important tool to further
increase our reassurance of edoxaban use in clinical practice, as has
been nicely shown for dabigatran.7 Second, although the interaction
between edoxaban and amiodarone seems to be less of an issue, the
current article still highlights the importance of taking into account
drug–drug interactions in clinical practice. While the novel oral
anticoagulants have fewer interactions than vitamin K antagonists,
we cannot ignore this important issue when prescribing these
drugs to patients who often have several co-morbidities and co-
medications.8 Finally, this article nicely illustrates the challenges
we face in the translation of trial findings to everyday patient care.
If the interpretation of interaction P-values and subgroup effects
remains difficult and controversial despite the availability of a large
randomized trial in a well-characterized patient population, then
finding the right drug for an individual patient is an even more daunt-
ing task. Only with carefully performed analyses from large studies
such as ENGAGE AF-TIMI 48 we will be able to make the right
decisions for our patients with whom we interact every day in
clinical practice.
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